180 Life Sciences Net debt/EBITDA
Qual é o Net debt/EBITDA de 180 Life Sciences?
O Net debt/EBITDA de 180 Life Sciences Corp. é 0.23
Qual é a definição de Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA de empresas na Setor Health Care em NASDAQ em comparação com 180 Life Sciences
O que 180 Life Sciences faz?
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Empresas com net debt/ebitda semelhantes a 180 Life Sciences
- Kapston Facilities Management tem Net debt/EBITDA de 0.22
- EOG Resources tem Net debt/EBITDA de 0.23
- Aptorum tem Net debt/EBITDA de 0.23
- Agenus Inc tem Net debt/EBITDA de 0.23
- Biolife Solutions Inc tem Net debt/EBITDA de 0.23
- Infinity Logistics tem Net debt/EBITDA de 0.23
- 180 Life Sciences tem Net debt/EBITDA de 0.23
- First Bancorp tem Net debt/EBITDA de 0.24
- Flexiroam tem Net debt/EBITDA de 0.24
- Trxade Health Inc tem Net debt/EBITDA de 0.24
- Mkango Resources tem Net debt/EBITDA de 0.24
- Ausmon Resources tem Net debt/EBITDA de 0.24
- Elmo Software tem Net debt/EBITDA de 0.24